earnings
confidence high
sentiment positive
materiality 0.90
ANI Pharmaceuticals reports record Q3 2025 revenue and raises full-year guidance
ANI PHARMACEUTICALS INC
2025-Q3 EPS
reported $2.15
vs consensus $1.79
▲ beat
(+20.2%)
- Record quarterly net revenues of $227.8 million, up 53.6% year-over-year.
- Purified Cortrophin Gel net revenues rose 93.8% to $101.9 million.
- Adjusted non-GAAP EBITDA of $59.6 million, up 69.8%.
- Raised 2025 total net revenue guidance to $854M-$873M and adjusted EPS to $7.37-$7.64.
- GAAP diluted EPS of $1.13 vs. net loss of $1.27 per share in prior year period.